Based on preclinical studies showing that CD8+ T lymphocytes of human immunodeficiency syndrome (HIV)-infected subjects have anti-HIV activities, a phase 1 study was undertaken to determine the safety and feasibility of infusing in vitro purified, activated, and expanded CD8+ cells as a therapeutic measure in seven patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC) or AIDS. Autologous CD8+ cells were first selectively isolated in monoclonal antibody-coated flasks from peripheral blood mononuclear cells recovered by leukapheresis. They were then cultured and expanded with phytohemagglutinin and recombinant interleukin-2 (rlL-2) before infusion. Five cycles of isolations and infusions of increasing numbers of CD8+ T cells were achieved in five of seven subjects. Five cycles could not be completed in two subjects with AIDS whose CD4+ cell counts were 548/pL. Infusions NTIVIRAL THERAPY in persons with acquired im-
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A munodeficiency syndrome (AIDS) or advanced human immunodeficiency virus (HIV) infection has failed to cure the infection or arrest the deterioration of the immune system.' One possible approach to treating the infection and reconstituting the immune system is to enhance the patient's cellular antiviral capacity. This study was undertaken to assess the feasibility of infusions of autologous in vitro expanded and activated CD8" cells as a mode of immunotherapy of HIV infection.
It is well-established that CD8+ cells from HIV-infected patients have specific anti-HIV cytotoxicity, and are able to kill HIV antigen-expressing targets in a major histocompatibility complex (MHC)-restricted as well as nonrestricted manner.24 There is suggestive evidence that the loss of these activated, circulating anti-HIV-specific cytotoxic T lymphocytes (CTL) is associated with the progression of d i s e a~e .~,~.~ The importance of CD8" CTL in protection against viral infection and its therapeutic effect is also supported by data obtained from various models of experimental virus infections. Prominent among these is the therapeutic effect of adoptive transfer of CD8" lymphocytes against murine cytomegalovirus infection in mice.7 Such antiviral CTL activity may be important in host defense against HIV and other viral infections to which HIV-infected subjects are prone.
In addition to their cytotoxic capacity, Walker et a18 observed that CD8' lymphocytes suppress the replication of HIV in peripheral blood mononuclear cells (PBMC) of patients with AIDS. Additional studies suggested that the virusinfected cells were not killed during the process: but rather that HIV replication was inhibited by a diffusible cytokine elaborated by CD8' cells." Kannagai et all' showed that the ability of PB CD4' lymphocytes of asymptomatic HIV-infected subjects to resist HIV infection was due to CD8" cells. This resistance was no longer seen in the leukocytes of patients with advanced disease.
of CD8+ cells alone were well tolerated. Four patients received rlL-2 by continuous infusion for 5 days with their final cycle of CD8+ cells. All developed reversible adverse effects attributable to rlL-2. After infusion, "'In-labeled CD8+ cells quickly accumulated in the lungs, with less than 10% of the labeled cells remaining in the circulation. After 2 4 hours, labeled CD8+ cells were reduced in the lungs, but increased and persisted in liver, spleen, and bone marrow. Four of five patients who were treated with multiple infusions of CD8+ cells have improved or remained clinically stable, and the fifth developed Pneumocystis carinii pneumonia but recovered. This study demonstrated that infusion of autologous, in vitro expanded and activated CD8+ cells was feasible and clinically well tolerated in five of seven subjects with advanced HIV infections. 0 1993 by The American Society of Hematology.
The rationale for the present study was that an inadequacy in anti-HIV and other antiviral CD8" cells may be related to the progression of disease, and infusion of in vitro expanded CD8" cells might restore some antiviral activity. To test this hypothesis, it was first necessary to obtain pure, autologous CD8" cells for infusion. Contamination with other T lymphocytes, particularly CD4" cells, could have resulted in the in vitro activation and reinfusion of HIV-infected T lymphocytes. Purification was achieved using a novel approach of selective capture of CD8' T lymphocytes on antibodycoated surfaces (Applied Immune Sciences, Inc, Menlo Park, CA)" from seven patients with advanced HIV infections. The purification, ex vivo activation and expansion, and the immunologic properties of the infused CD8' cells, as well as the changes of anti-HIV cytotoxicity and lymphocyte subset composition in the PB in patients after infusions, are described in detail e1sewhere.l2-I4 Data presented here concern the clinical aspects of patients who received repeated intravenous infusions of autologous in vitro activated effector cells in escalating doses of lo8 to 10" cells. These include the safety and toxicity of this procedure, the hematologic changes 2094 HO ET AL after CD8+ infusions, and the effect of infusions on the distribution of ' 'In-labeled autologous CD8' lymphocytes with or without concomitant administration of recombinant interleukin-2 (rIL-2).
MATERIALS AND METHODS
Study design. This study was Protocol 080 of the National Institutes of Health (N1H)-supported AIDS Clinical Trials Group (ACTG). It was approved by the ACTG and the University of Pittsburgh Institutional Review Board. The design of this single-center, open, phase I study is shown in Table 1 . Its purpose was to evaluate the safety and efficacy of reinfusion of in vitro rIL-2-activated and expanded CD8+ T lymphocytes in patients with AIDS-related complex (ARC) or AIDS. Each patient was to undergo 5 to 6 serial leukaphereses at 3-week intervals to allow for purification, activation, and expansion of CD8+ cells. Autologous CD8+ cells were captured and expanded in culture for 3 weeks in the presence of rIL-2 and then reinfused intravenously into the patients. As shown in Table 1 , the protocol called for the infusion of 10' cells at week 4, IO9 at week 7, 1Olo at week IO, and 10'"at week 13. Ten percent ofthe cells used in week 13 were labeled with "'In for whole body biodistribution studies. At week 16, the patient was hospitalized and again received IOlOcells, 10% of which were "'In-labeled. At the same time, a continuous intravenous infusion of 1 X lo6 IU/mZ per day of rIL-2 (Hoffmann-La Roche, Nutley, NJ) was begun and extended over 5 days. This 5-day treatment was performed to determine the feasibility of concurrent administration of rIL-2 should it become necessary to maintain the infused CD8+ cells in a viable and activated state or to augment their antiviral activity.
Inclusion criteria for the patients were HIV antibody positivity determined by enzyme-linked immunosorbent assay (ELISA; Genetic Systems, Seattle, WA), and either isolation of HIV from PBMC or presence of HIV p24 antigenemia (Abbott Laboratories, Chicago, IL), CDC group IV HIV clinical status of severe ARC or AIDS,I5 and a Karnofsky score of 270. Entry criteria also initially included a CD4+ cell count of ?5O/pL but s400/fiL and a CD8+ cell count of 2200/pL. This was later modified to include patients with lower T-cell counts, after early studies showed no detrimental effect of the study procedures on PB lymphocyte numbers. The patients must have received treatment with zidovudine (ZDV) for at least 6 weeks before their first CD8+ cell infusion. ZDV was continued at a minimum of 300 mg per day through 20 weeks after the last infusion, unless medically contraindicated. The patients were treated with oral antibiotics or aerosolized pentamidine as prophylaxis for Pneumocystis carinii if their CD4 counts were less than 200/pL. The granulocyte count had to be greater than l,OOO/pL, platelets greater than 75,OOO/pL, and hemoglobin greater than 9.5 g/dL. Exclusion criteria included active bacterial or other opportunistic infections that required treatment. Patients who had received biologic response modifiers within 60 days before entry were excluded.
Each patient was assessed clinically and by laboratory procedures immediately before and after infusions, and was observed for up to 27 weeks from the beginning of the study. Laboratory parameters monitored included routine hematologic and blood chemistry tests, lymphocyte subset determinations, HIV p24 antigen determinations, and HIV cultures.
Leukaphereses were performed using a model CS-3000 Fenwal separator (Fenwal Laboratories, Inc, Deerfield, IL). Leukocytes obtained were processed under sterile conditions to recover PBMC and subsequently to capture and expand CD8+ T lymphocytes. Details of the procedures used and results of the purification, activation, and expansion of CD8+ cells are described in a companion paper (Whiteside et all3). Briefly, CD8+ T cells were selected from PBMC using 150-cm2
Patients.
Purification and expansion of uutologous CD8+ T cells. CELLector flasks coated with anti-CD8 monoclonal antibody (MoAb; Applied Immune Sciences). Captured CD8+ cells were cultured in RPMI 1640 medium containing 10% (vol/vol) human AB serum supplemented with phytohemagglutinin (PHA) (0.1 pg/mL) and 300 IU/mL of rIL-2. The expanding cells were maintained at the density of 0.5 X lo6 cells/mL by repeated additions of fresh growth medium to the cultures. At the end of the culture period (2 to 3 weeks), the cells were harvested, counted, washed, and checked for sterility. All cultures were examined for cytotoxicity and phenotypic markers before infusions to patients.
Cytotoxicity assays. A modification of the method of Walker et a12 was used to assess HIV-specific CTL response^.'^ Briefly, B-lymphocyte cell lines (LCL) were established from the patients' blood by immortalization with Epstein-Barr virus. The LCL were infected overnight with recombinant vaccinia viruses expressing either the Escherichia coli lac z gene, or the gag, pol, and env and genes of HIV type I strain IIIB (courtesy of B. Moss, NIH). For assay of natural killer (NK) or lymphokine-activated killer (LAK) cell activities, K-562 and Daudi cells were used as target cells. The target cells were labeled with Na2'Cr04 and added to round-bottom microtiter wells.
Effector cells consisting of either autologous PBMC or purified, propagated CD8' lymphocytes were added to the microwells to achieve a final effector cel1:target cell ratio of 50:1, 25:1, 12.5:1, and 6.25:l. Controls consisted of medium plus target cells alone (for spontaneous release of 5'Cr) and target cells plus detergent (for total release of "Cr). After 4 to 5 hours of incubation at 3 7 T , the cell supernatants were harvested and counts per minute (cpm) of radioactivity were determined in a gamma counter. The percent lysis of the target cells was calculated as: % lysis = ([experimental cpm -spontaneous cpm]/[maximum release cpm -spontaneous release cpm]) X 100. Results were expressed as the number of lytic units (LU) present in lo7 effector cells, with 1 LU defined as the number of effector cells required for 20% lysis of 1 X lo3 target cells.
Isolation of HIV from CD8+ cell preparations and from PBMC of study subjects was performed by the consensus ACTG protocol as described by Gupta et al.I6 Briefly, 10 million fresh PBMC from subjects were cocultivated with 5 X IO6 PHA-stimulated fresh PBMC obtained from normal donors in 10 mL of RPMI 1640 medium containing 20% fetal bovine serum and 5% natural IL-2 (Cellular Products, Buffalo, NY). Thereafter, 3 X IO6 PHA-stimulated normal cells were added to the culture twice a week for a period of 4 weeks. Culture supernatants were harvested every 3 to 4 days and tested for the presence of HIV by the antigen capture test (Dupont, Wilmington,
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DE; Abbott Laboratories). A culture was considered positive if two serial supernatant samples were positive, with the later sample demonstrating a minimum fourfold increase in p24 antigen to at least Serum samples and CD8+ cell preparations were tested for HIV p24 antigen with a commercially available ELISA kit (Abbott Laboratories). The lower limit of detectability for this assay was approximately 50 pg/mL.
To determine the whole body distribution and the clearance of CD8+ cells infused into the blood stream, plasma-free CD8+ cells were radiolabeled with "'In Oxine by incubation of 1 X lo9 cells with 500 MCi of indium oxine (Amersham, Inc, Arlington Heights, IL) in normal saline at room temperature for 30 minutes.17 After washing and counting, the labeled cells were admixed with the remaining 9 X 1Olo unlabeled CD8 cells and infused over IO to 15 minutes intravenously. At the start of infusion and periodically thereafter (0 and 5 minutes; end of infusion; 20, 40, 60, 80, 100, and 120 minutes; and 24, 48, 72, 96, and 120 hours), blood samples were taken for clearance of "'In. Urine was collected in 24-hour intervals for up to 7 days to measure whole body elimination.
To determine organ distribution of labeled cells, the patient was placed and scanned under a nuclear medicine gamma-camera with single photo emission computed tomographic (SPECT) capabilities (either the Siemen's Orbiter or Trionix Biad). Data were collected and digitized for quantification using Siemens' Software (Siemens Gammasonic, Hoffman Estates, IL). The whole body and individual organ biodistributions of the "lIn-labeled CD8' cells was determined by quantitative analysis of the counts per pixel in the whole body. Organ and tissue volumes were adjusted for tissue attenuation and distance by calculating the geometric means of the counts in the anterior and posterior projections. The total marrow distribution of the "lln was determined by extrapolating from the counts observed over three lumbar vertebrae, and multiplying by 29.7. The three vertebrae represented 3.37% of the total bone marrow mass in the "standard' human according to the Medical Interval Dosimetry Group at ORAU (Oak Ridge, TN) (personal communication, August 1991). The relative shift in radioactivity among the lung, liver, spleen, and bone marrow was determined over time by calculating the activity in each region of interest at a given time point divided by the total activity in the four organs/tissues. 100 pg.
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Biodistribution of "'In-radiolabeled CD8+ lymphocytes. The number of cells are listed in the sequence they were administered a t intervals of about 3 weeks as specified by the protocol described in Table 1 .
Abbreviation: ND, not done because of inadequate number of CD8+ cells for culture and expansion.
RESULTS
Patients. Seven white, male subjects entered the study, five of whom were homosexual, one heterosexual, and one bisexual. Their median age at study entry was 37 years (Table  2) . Four patients had symptomatic HIV infection consistent with ARC, and three had been previously diagnosed with AIDS-defining conditions (Table 2 ). Entry CD4+ cell counts ranged from 8 to 8 17/pL, with a median value of 148/pL, and entry CD8' cell counts ranged from 147 to 1312/pL, with a median value of 855/pL ( Table 2 ).
The numbers of CD8' cells infused each time in our seven subjects are given in Table 3 . The details of the preparation of these cells, including the initial number of CD8 cells collected and the number obtained after purification and after in vitro expansion, are given in the companion paper (Whiteside et all3). After capture on CELLector CD8+ flasks and 14 to 2 1 days of expansion of purified CD8 cells, we were able to complete 5 to 6 reinfusions in five patients (patients no. 1, 2, 4, 6, and 7). The infusion of 10'' CD8' T cells, as specified in the protocol for the last 2 cycles (Table l) , was achieved only in patient no. 1. In patients no. 2, 4, 6, and 7, a maximum of 0.7 X IO9 to 3.3 X lo9 cells was infused (Table 3) .
Patients no. 3 and 5 were the two patients from whom we could not prepare enough CD8+ cells for the required number of infusions. Only 0.35 X 10' CD8+ cells could be obtained from patient no. 3 after 1 leukapheresis, and they did not expand in vitro. No in vitro culture or reinfusions took place (see Whiteside et all3). Despite the fact that the CD8' cells of patient no. 5 expanded a mean of 31-fold after 4 leukaphereses and 3 in vitro culturing, enough CD8+ cells were obtained only for one infusion of 1 X 10' cells. Both of these patients had AIDS, CD4+ counts less than 50/pL on entry, and subsequently have died.
Four of the seven subjects (patients no. I , 4, 6, and 7), as mandated by the protocol, received 1 .O X lo6 IU/m2 of rIL-2 daily by continuous intravenous infusion for 5 days during and after their final CD8' cell infusion. Three subjects (patients no. 2, 3, and 5) did not receive rIL-2; patients no. 3 and 5 were removed from the study before this phase due to poor CD8+ cell expansion, as already described, and patient
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no. 2 refused rIL-2 because of concern about potential side effects.
As described by Whiteside et al,l3 the cells obtained by capture and subsequent culture in the presence of PHA and rIL-2 were highly enriched for CD3'CD8+ cells (95% to 99%). No CD4+ T cells and CD14' monocytes were detectable, and the percentage of CD19' B cells was less than 1%. The expanded cells were mainly CD8+CD 1 I b-, a subset associated with cytotoxic T cells, 29% to 84% of the expanded cells were activated (HLADRl+), and most expressed the CD29 antigen associated with the memory or helper-inducer T-cell Samples of all preparations of CD8+ cells prepared for infusion were tested for p24 levels. Samples of such preparations from patients no. 2,4,5,6, and I were also cultured 48 hours or less before infusion in patients for HIV by cocultivation with fresh PBMC. None was positive. Samples from patient no. 1 were not cultured because this was not the routine early in the study. Patient no. 3 was not reinfused.
Before infusion, cell cultures were assessed for cytotoxicity in 51Cr release assays against a panel of targets, including K562, Daudi, and autologous B-LCL infected with vaccinia virus-HIV gene constructs. This is given in detail else~here,'~
Characteristics of infused CD8' cells.
but a summary is provided in Table 4 . It is evident that, compared with activity in PBMC obtained either before or after CD8+ cell infusions, the CD8+ cell product used for infusions was significantly enriched for specific CTL activity against autologous LCL targets expressing HIV pol, env, and gag proteins, as well as for NK cell and LAK cell activities. PBMC from our patients expressed both HLA-specific and nonspecific cytotoxic activities. There is a slight increase in activity against HIV-expressing targets after infusion of CD8+ cells, but this was not significant.
Effects of infusions of CD8+ cells on hematologic parumeters.
It was of interest to determine the effects of this form of therapy with or without rIL-2 infusions on hematologic parameters. The numbers of total white blood cells, lymphocytes, granulocytes, and platelets and levels of hemoglobin were determined at baseline, just before infusion, and after the last infusion administered without rIL-2 ( Table 5 ) . The data in Table 5 are given as medians of values between subjects. The first data column "baseline" shows the medians of the individual subject's mean values obtained at the three baseline visits starting 3 weeks before the first infusion and up to and including values for blood samples taken about 6 hours before this infusion. At this time, the subjects had a White blood cells
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white blood cell count, platelet count, and hemoglobin level within the normal range. The proportions of white blood cells that were lymphocytes and neutrophils were 4 I % and 4770, respectively. To look at the effect of infusion, the next two columns give hematologic values for samples taken at the time of the last infusion administered without concurrent rIL-2 infusion.
As the earlier infusions were of low numbers of cells (Tables  1 and 3) , the infusion for which these data were obtained represents hematologic response to the highest dose of cells (lo9 to 10") (see Table 3 and above). There is no statistical difference between the preinfusion and postinfusion counts. The fourth and fifth columns of data show the changes observed when approximately the same number of CD8' cells were infused as shown in the two previous columns but when rIL-2 was administered for 5 days starting at the time of CD8' infusion to maintain the activated state of the CD8+ cells. The lymphocyte counts decreased sharply during rIL-2 infusion to 14% (as opposed to 41% at baseline) of the white blood cell count (data column 4), with a smaller decline in platelets. As shown in the fifth column, there was a sharp increase in the white blood cell count to 126% of baseline and 1 19% of the count during IL-2 infusion and the lymphocytes rebounded from 14% of the white blood cell count to almost four times the lymphocyte counts obtained during IL-2 infusion. This lymphopenia and rebound has been previously described in cancer patients receiving systemic rIL-2 treatment.",* '
The follow-up data (last column) includes all observations made at least 14 days and up to 14 weeks after the last infusion. The values shown are not statistically different from baseline (ANOVA).
The immediate and long-term effects of infusions on CD4+ and CD8+ lymphocyte subsets were also analyzed (Fig I) . During the period of infusions, the numbers of CD4+ and CD8' lymphocytes were monitored 6 hours before and 18 hours after each infusion with CD8' cells. There were fluctuations, but no consistent increase or decrease in the absolute Number showing adverse effectlnumber receiving rlL-2 number of the circulating CD8' T cells 24 hours after infusion of CD8' cells. There were transient decreases in numbers of circulating CD8+ and CD4+ cells by 24 to 48 hours after the beginning of infusion of rIL-2 and a rebound by 72 hours after the end of the infusion (patients no. I, 4, 6, and 7). These observations are consistent with observations reported by others in HIV-infected patients receiving systemic rIL-2 therapy.'* Overall, the CD4' or CDSt counts did not change consistently as a result of CD8+ cell infusions. CD8+ counts in the blood did not increase after infusions largely because the numbers that remained in the vascular system were insufficient to affect such counts (see below). The PBMC of six of seven subjects were cultured for HIV on two to three occasions before the first apheresis, two to three times during the course of the study, and at least once during the follow-up period. Only 3 of 25 cultures, all from different subjects, were negative after 28 days of incubation. All remaining cultures were HIV positive after 3 to 17 days of incubation. Serum p24 antigen assays performed at the same times were consistently negative in all but two subjects (patients no. 5 and 7 ) , in whom antigenemia was seen in 50% of the samples, with no relation to treatment.
Patients no. 3 and 5 had advanced HIV infection at enrollment. Patient no. 3 received no adoptive therapy and died 16 months later. Patient no. 5 had only I infusion and died 4 months after enrollment.
All five patients (patients no. 1, 2,4,6, and 7) who received 5 or more infusions are still living after a minimum of 6 months and a maximum of 2 years after completion of the study. Four remained clinically stable with no AIDS-defining opportunistic infections. One (patient no. 1) achieved a 20-
Virologic outcome.
Clinical outcome and toxicities.
Ib weight gain while on the study, which was sustained I year after the patient completed adoptive immunotherapy. The fifth patient (patient no. 7) had ARC at entry, developed P carinii pneumonia after 4 infusions, but has remained clinically stable after completing his fifth infusion.
No toxicities were associated with the leukapheresis procedures or with the administration of CD8+ cells alone, except for nausea on one occasion in one patient, and one episode of fatigue occurring after infusion in another patient. The main toxic effects that were associated with infusions of rIL-2 are tabulated in Table 6 .
Vascular and organ distribution oj" "'In-labeled CD8+ cells. During the last two infusions, 10% of the cells were labeled with "'In, injected intravenously together with unlabeled cells, and, after infusion, nuclear scans were performed in four patients. Data collected from peripheral blood for determination of vascular clearance of ' "In-labeled cells were available from four patients without rIL-2 and three patients receiving rIL-2.
Multiple early samples collected within 2 hours after the start of infusion of " 'In-labeled CD8' lymphocytes showed that a maximum of 6.1 % rir 3.2% of the injected radioactivity was initially present in circulation. Vascular clearance of the label was biphasic. The initial phase, starting from maximum levels seen 40 to 60 minutes from the start of infusion, lasted 20 to 40 hours, with a mean tl/' of 16.2 k 6.5 hours. In the second phase, the mean t,,, was 79.5 f 44.5 hours, but in two instances no further clearance of label was seen from 40 hours up to I 17 hours. There were no significant differences between the clearance in the presence or absence of concomitant rIL-2 infusions. However, the fraction of label cleared with first phase kinetics was slightly but not statistically significantly higher (73.3% f 11.5%) with IL-2 than without (55.0% f 4.1%). The fraction of the "'In label appearing in the urine during the first 48 hours was 7% to 10%.
The distribution of the label in major organs was monitored by total body imaging (Table 7 and Fig 2) . It was visually shown that, with or without rIL-2, accumulation of labeled cells in the lungs began immediately (data not shown). After 4 hours, an average of 53% of the counts had accumulated in the lungs in the absence of rIL-2, and 72% when rIL-2 was administered. Smaller amounts of label (7% to 14%) were detected in the liver, spleen, and bone marrow. The accumulation of labeled cells gradually increased in these latter organs, whereas label in the lungs decreased over 48 hours. Comparing the amount of label in the lungs from 24 to 96 hours, there was a consistent trend toward greater retention in the lungs of the patients who received rIL-2; correspondingly, there was less in liver, spleen, and marrow.
DISCUSSION
This is the first report of a phase 1 study of the infusion of autologous CD8' cells in patients with AIDS or ARC. In five of the seven patients, the required 5 cycles of leukaphereses, in vitro expansion, and reinfusion were completed. In vitro expansion was adequate in one case to allow us to reinfuse IO'" cells, but in the other four, a maximum of 1.5 X IO9 to 3.4 X IO9 cells were reinfused. In two patients with AIDS with low CD4' cell counts, one of whom had p24 antigenemia, the 5 cycles of infusion could not becompleted. because adequate numbers of CD8' T cells could not be prepared. Either not enough pure CD8' T cells could be obtained from the patient's PBMC after leukapheresis or there was inadequate in vitro expansion. However, one ARC patient (patient no. 7) with an entry CD4+ cell count of only 46/pL successfully underwent 5 cycles of reinfusion. These data show that expansion and reinfusion of autologous CD8+ cells is feasible in patients with CD4' cell counts greater than 150/pL. Patients with CD4+ cell counts less than 50/pL and p24 antigenemia may present difficulties. There is abundant evidence that HIV-infected and AIDS patients have problems with T-cell proliferation or colony formation in the presence of IL-2,2'-2s although specific information for CD8' cells is lacking in the literature.
The infusions of CD8+ cells in the absence of rIL-2 were very well tolerated. This is consistent with the experience of others who infused cultured unseparated T lymphocytes obtained from human solid tumors and also found the procedure to be well t~l e r a t e d .~~.~' The main side reactions in the present study were consistent with those expected from other HIV infection.2022 However, all four patients who received rIL-2 successfully completed 5 days of administration of rlL-2 as planned, and were discharged on day 6. It remains uncertain if CD8' cells transferred with IL-2 were more effective than those without IL-2.
This study is also the first report of organ distribution and vascular clearance of highly purified, adoptively transferred CD8' lymphocytes in humans. After intravenous injection. less than 10% of indium-labeled cells were detectable in the vascular system. The cells remaining in the circulation had a biphasic clearance pattern with little urinary excretions of the label. Most of the labeled cells were immediately concentrated in the lung, as documented using a gamma camera. The counts then gradually decreased over 96 hours and were redistributed to the reticuloendothelial system (liver and spleen and bone marrow). This type of count distribution is commonly seen in tumor-bearing animals or humans treated with adoptive cellular immunotherapy.26v28 In fact, the distribution patterns seen by us with purified CD8' cells were similar to those reported by Lotze et aI2' and Kradin et a12' for autologous T cells grown in vitro in the presence of rlL-2. There was rapid uptake in the lungs and the latter investigators also found only I% to 2% of injected, labeled cells in the vascular sy~tem.~' "'Indium-labeled cells are unsatisfactory for the study of long-term biodistribution of lymphocytes because of the short half-life of indium (2.8 days). damage to lymphocytes caused by autoirradiation, and spontaneous release of "'[In] from cells.29 Rosenberg et at' ' used tumor-infiltrating lymphocytes (TIL) genetically labeled with a neomycin resistance gene to avoid these disadvantages in distribution studies. Using polymerase chain reaction, labeled TILS were found in the circulation and in tumor tissue for up to 2 months after infusion. Similar studies will be desirable to determine the long-term distribution of CD8+ cells in HIV-infected subjects and, spestudies when rIL-2 was infused in patients with or without cifically, to demonstrate the presence of the effector CD8' 
